NCT04566393: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies |
|
|
| Available | N/A | | US | Ulixertinib (BVD-523) | xCures, Cancer Commons | Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation | | | | |
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles |
|
|
| Recruiting | N/A | 30000 | Europe, Canada, US, RoW | MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint | Agendia | Breast Cancer | 04/37 | 12/37 | | |
